The US Food and Drug Administration has publicly listed the names of nearly 40 pharma companies that may have been denying access to reference samples for generic drug manufacturers, thereby delaying generic competition. Is this ‘name and shame’ strategy justified, and just how big is the issue of pharma companies holding back reference samples from generic competitors after patent expiry? Chris Lo investigates in the latest issue of Pharma Technology Focus